CHICAGO, NY, UNITED STATES, January 21, 2025 /EINPresswire.com/ -- The global 𝐥𝐢𝐯𝐞𝐫 𝐟𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 is set to witness significant expansion over the coming decade, with revenues anticipated to rise from 𝐔𝐒𝐃 𝟏𝟕.𝟓𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 to an impressive 𝐔𝐒𝐃 𝟓𝟏.𝟏𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟑, achieving a robust compound annual growth rate (𝐂𝐀𝐆𝐑) 𝐨𝐟 𝟏𝟎.𝟖% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝 𝟐𝟎𝟐𝟓-𝟐𝟎𝟑𝟑.

𝐓𝐡𝐞 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:- https://www.astuteanalytica.com/request-sample/liver-fibrosis-treatment-market

This remarkable growth is driven by advancements in diagnostic technologies, increasing prevalence of liver diseases, and a heightened focus on developing innovative therapeutic solutions. Liver fibrosis, a condition often resulting from chronic liver damage, has spurred global research and development efforts to address its progression effectively.

The demand for effective treatment options is bolstered by a growing awareness of liver health and government initiatives aimed at combating liver-related disorders. Moreover, pharmaceutical companies are actively investing in cutting-edge therapies, including antifibrotic agents and gene therapies, to meet the rising demand for advanced care solutions.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬

𝐃𝐫𝐢𝐯𝐞𝐫: 𝐑𝐢𝐬𝐢𝐧𝐠 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐋𝐢𝐯𝐞𝐫 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬

Liver disease accounts for 2 million deaths annually, representing 4% of global mortality, with liver cancer contributing 600,000–900,000 deaths each year. The primary drivers of liver-related deaths include complications from cirrhosis and hepatocellular carcinoma, with viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD) as leading causes. Rising metabolic risk factors and an aging population are expected to double the burden of advanced NAFLD by 2030. The rising prevalence of liver diseases and associated complications is driving demand for innovative treatments, positioning the liver fibrosis treatment market for significant growth.

This growing burden is pushing healthcare systems to invest in advanced diagnostic tools and treatment options, including antifibrotic drugs and cell therapies. Additionally, the increasing awareness about liver diseases and the adoption of routine screening programs are contributing to earlier detection and treatment, further boosting the market. As liver fibrosis progresses and leads to more severe complications, such as cirrhosis and liver failure, there is a strong incentive for both healthcare providers and pharmaceutical companies to develop and introduce innovative therapies. This demand, fueled by the rising prevalence of the disease, is shaping the growth trajectory of the liver fibrosis treatment market.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐎𝐫𝐚𝐥 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb
• Johnson and Johnson
• Novartis AG
• Vertex Pharmaceuticals Incorporated
• Pfizer Inc.
• FibroGen, Inc.
• Inventiva Pharma
• Pharmaxis Limited
• Other Prominent Players

𝐑𝐞𝐚𝐝 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐈𝐧𝐝𝐞𝐱 𝐨𝐟 𝐟𝐮𝐥𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐭𝐮𝐝𝐲 𝐚𝐭 @ https://www.astuteanalytica.com/industry-report/liver-fibrosis-treatment-market

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐓𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭

𝐁𝐲 𝐃𝐫𝐮𝐠 𝐓𝐲𝐩𝐞


• Peroxisome Proliferator-Activated Receptors (Par)-Alpha Agonist
• Ace Inhibitors
• Hepatotropic Drug
• Others

𝐁𝐲 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧

• Chronic Liver Diseases
• Hepatitis C
• Non-Alcoholic Steatohepatitis (NASH)
• Non-Alcoholic Fatty Liver Disease (NAFLD)
• Others

𝐁𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫

• Hospitals
• Specialty Clinics
• Others

𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

𝐁𝐲 𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐲

• North America
• The USA
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭@- https://www.astuteanalytica.com/request-sample/liver-fibrosis-treatment-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐬𝐭𝐮𝐭𝐞 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyse for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg
Astute Analytica
+1 888-429-6757
email us here
Visit us on social media:
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.